Today, February 5, 2026, San Diego-based biotechnology company AnaptysBio, Inc. (Nasdaq: ANAB) revealed plans for its involvement in various investor conferences. Daniel Faga, the president and CEO of Anaptys, along with other key executives, will be engaging in these conferences. AnaptysBio specializes in developing groundbreaking immunology treatments and is currently in the clinical stage of its operations.